Elena Elez, MD, PhD, on Updated Survival Data From the BREAKWATER Trial
2025 ASCO Annual Meeting
Elena Elez, MD, PhD, of Vall d’Hebron Institute of Oncology, presents updated overall survival data as well as progression-free survival data from the BREAKWATER trial of the first-line use of encorafenib, cetuximab, and mFOLFOX6 in BRAF V600E–mutant metastatic colorectal cancer (LBA3500).
Transcript
Disclaimer: This video transcript has not been proofread or edited and may contain errors.
We know that between 8 to 12% of patients with metastatic colorectal cancer have BRAF V600E–mutated metastatic colorectal cancer. What we know from these illnesses is that it's a poor prognosis group of patients, so the first-line treatments that we have have really limited efficacy, and this was the basis for developing a phase three clinical trial in this patient population. We know as well that encorafenib is an ATP-competitive BRAF inhibitor that, combined with cetuximab, was approved for treatment in the second and third line of metastatic colorectal cancer in this patient population. What we are doing now is exploring the combination of encorafenib, cetuximab, and FOLFOX in frontline therapy for this patient population, compared to encorafenib and cetuximab alone or the standard of care, which is chemotherapy combined with bevacizumab or not. The dual primary endpoint of this clinical trial was progression-free survival and overall response rate, and the secondary objective of this clinical trial was overall survival. Indeed, the results of the BREAKWATER trial were presented at the beginning of 2025. We had the results of overall response rate—the study met one of its primary endpoints—and what we are presenting now at ASCO 2025 are the results of progression-free survival, the other dual primary endpoint, and results on overall survival. Regarding the patient population, it was well balanced. It's nice to see that we have a representation of patients with high tumor burden, meaning three or more metastatic sites of metastasis as well as liver metastasis. Regarding the results on overall survival, the combination of FOLFOX, encorafenib, and cetuximab was statistically significant and clinically meaningful, superior compared to the standard of care. In this case, we found 30 months of overall survival for the patients treated with encorafenib, cetuximab, and FOLFOX, and 15 months for those patients treated with the standard of care. This represents a paradigm change in the treatment of metastatic colorectal cancer harboring a BRAF V600E mutation, and this regimen will be a new standard of care in the frontline setting for this patient population.
The ASCO Post Staff
Mazyar Shadman, MD, PhD, of Fred Hutchinson Cancer Center and the University of Washington, presents results from arm D of the SEQUOIA trial, which evaluated the combination of zanubrutinib and venetoclax in treatment-naive patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (Abstract 7009).
The ASCO Post Staff
Clifford A. Hudis, MD, FASCO, FACP, Chief Executive Officer of ASCO, discusses ASCO Guidelines Assistant, an AI-based collaboration between ASCO and Google Cloud which draws from ASCO’s evidence-based, published clinical practice guidelines, offering clinicians ready access to timely, trustworthy information.
The ASCO Post Staff
Yelena Y. Janjigian, MD, of Memorial Sloan Kettering Cancer Center, presents event-free survival data from the phase III MATTERHORN trial of the PD-L1 inhibitor durvalumab plus FLOT (fluorouracil, leucovorin, oxaliplatin and docetaxel chemotherapy) in patients with resectable gastric or gastroesophageal junction (GEJ) cancer (LBA5).
The ASCO Post Staff
Frank A. Sinicrope, MD, of Mayo Clinic Rochester, reviews findings from the randomized Alliance A021502/ATOMIC trial, which studied standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III DNA mismatch repair–deficient (dMMR) colon cancer (LBA1).
The ASCO Post Staff
Praful Ravi, MBBChir, MRCP, of Dana-Farber Cancer Institute, presents findings from an ICECaP individual patient-data meta-analysis of randomized controlled trials on a treatment strategy used in high-risk localized prostate cancer (Abstract 5013).